Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Brandon Robert Mancini | Researchclopedia

Back to researchers

Brandon Robert Mancini

10

Works

7

Citations

2

h-index

0

i10-index

Research Topics

Radiopharmaceutical Chemistry and Applications Prostate Cancer Treatment and Research Medical Imaging Techniques and Applications

Top Works

[ <sup>212</sup> Pb]VMT-α-NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and preliminary report for expansion participants.

Þorvarður R. Hálfdánarson,Lilja B. Sólnes,et al.

20252 citations

Neuroendocrine Tumor Research Advances

Lung Cancer Research Studies

Augmented alpha-beta PSMA radioligand therapy in metastatic prostate cancer: Analysis of prognostic factors for survival.

Harshad Kulkarni,Jaya S. Khushalani,et al.

20222 citations

COMBAT: A study of <sup>64</sup>Cu-SAR-BBN and <sup>67</sup>Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer.

Luke T. Nordquist,Eva Lengyelova,et al.

20242 citations

SABRE: Assessment of safety and efficacy of <sup>64</sup>Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.

Luke T. Nordquist,Eva Lengyelova,et al.

20242 citations

Ga-68 PSMA-11 impacting prostate cancer management in a real-world setting: A pilot experience using the total-body PET/CT scanner.

Harshad Kulkarni,Dan Rogers,et al.

20230 citations

Safety and preliminary efficacy results of [ <sup>212</sup> Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs).

Þorvarður R. Hálfdánarson,Richard L. Wahl,et al.

20260 citations

Phase 1 dose escalation and expansion of AB001 in patients with metastatic castration resistant prostate cancer (mCRPC): The ARTISAN trial.

Brandon Robert Mancini,Oliver Sartor,et al.

20260 citations

Pharmacokinetics and dosimetry of lutetium Lu 177 zadavotide guraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the ECLIPSE sub-study.

Frankis Almaguel,A. Kelly,et al.

20260 citations

A phase 1/1b study of the theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) in patients with glypican-3-positive (GPC3+) previously treated unresectable hepatocellular carcinoma.

Brandon Robert Mancini,Medhat Osman,et al.

20260 citations